Cyclacel Pharmaceuticals, Inc. (CYCC)
| Market Cap | 36.14M |
| Revenue (ttm) | 150,000 |
| Net Income (ttm) | -8.15M |
| Shares Out | 4.86M |
| EPS (ttm) | -3.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $7.43 |
| Previous Close | $7.36 |
| Change ($) | 0.07 |
| Change (%) | 0.95% |
| Day's Open | 7.38 |
| Day's Range | 7.23 - 7.52 |
| Day's Volume | 145,097 |
| 52-Week Range | 3.21 - 15.40 |
– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors – – Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer – – $7 Million Strategic Investm...
BERKELEY HEIGHTS, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing inno...
Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 2020 Results - Earnings Call Transcript
BERKELEY HEIGHTS, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innova...
A patient with MCL1 amplified endometrial cancer achieved partial response (PR) with 92% target tumor shrinkage on singe agent fadraciclib A patient with MCL1 amplified endometrial cancer achi...
BERKELEY HEIGHTS, N.J., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innov...
BERKELEY HEIGHTS, N.J., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innov...
BERKELEY HEIGHTS, N.J., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing inn...
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2020 Results - Earnings Call Transcript
- Conference Call Scheduled August 12, 2020 at 4:30 p.m. ET - - Conference Call Scheduled August 12, 2020 at 4:30 p.m. ET -
BERKELEY HEIGHTS, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing in...
Investors will focus on its pipeline progress when Cyclacel (CYCC) reports Q2 results.
-- Characterization of fadraciclib published in peer-reviewed journal shows specificity against
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2020 Results - Earnings Call Transcript
- Conference Call Scheduled May 12, 2020 at 4:30 p.m. ET -
BERKELEY HEIGHTS, N.J., April 24, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing i...
Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) shares were crushed on Tuesday after the company announced the pricing of a secondary offering.
BERKELEY HEIGHTS, N.J., April 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing i...
Shares of nanocap biopharma Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) were ripping higher Monday following the announcement of a partnership to study two of its drugs to treat complications ...
-Evaluation of Fadraciclib and Seliciclib to Promote Apoptosis of Inflammatory Neutrophils in the Setting of COVID-19 Lung Injury- -Evaluation of Fadraciclib and Seliciclib to Promote Apoptosi...
BERKELEY HEIGHTS, N.J., April 14, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing i...
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2019 Results - Earnings Call Transcript
We expect Cyclacel (CYCC) to provide updates on its pipeline when it releases fourth-quarter 2019 results.
CYC065-venetoclax combination was well tolerated in AML and CLL dose escalation studies CYC065-venetoclax combination was well tolerated in AML and CLL dose escalation studies
Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q3 2019 Results - Earnings Call Transcript
BERKELEY HEIGHTS, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing i...
BERKELEY HEIGHTS, N.J., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing in...
BERKELEY HEIGHTS, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing i...
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2019 Results - Earnings Call Transcript
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2019 Results - Earnings Call Transcript
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2018 Results - Earnings Call Transcript
About CYCC
Cyclacel Pharmaceuticals, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemia... [Read more...]
| Industry Biotechnology | Founded 1992 |
| CEO Spiro Rombotis | Employees 12 |
| Stock Exchange NASDAQ | Ticker Symbol CYCC |
Analyst Forecasts
According to 2 analysts, the average rating for CYCC stock is "Strong Buy." The 12-month stock price forecast is 21.33, which is an increase of 187.08% from the latest price.